Ben Zvi Shmuel reported PLX

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0001935668-26-000002

Machine-readable

Structured copy

Timestamps

Event (reported)

Sep 3, 2026

Published

Sep 4, 2026

Ingested by INSIDER

Nov 5, 02:18 UTC

Last re-read

Nov 5, 02:18 UTC

Extracted facts

Filer

Ben Zvi Shmuel

Role

Director

Transaction

Grant or awardAs filed: “A”

Asset

Protalix BioTherapeutics, Inc. — Stock Options (Right to Buy)

Ticker

PLX

Shares

17.0K

Price per share

$0

Execution date (reported)

Sep 3, 2026

Owned after transaction

17.0K shares

Days from execution to publication

1

What this establishes

Ben Zvi Shmuel filed this Form 4 reporting a grant or award of PLX on Sep 3, 2026. It became public on Sep 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

Director

Ben Zvi Shmuelcik:0001935668

Issuer

Protalix BioTherapeutics, Inc.cik:0001006281

Revision history · 0

No field has changed since this record was first ingested.